HLA-DR6: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 25: | Line 25: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:DR Illustration.PNG|DR Illustration | |||
</gallery> | |||
Latest revision as of 06:06, 3 March 2025
HLA-DR6 is a human leukocyte antigen serotype within HLA-DR serotype group. The serotype is determined by the antibody recognition of HLA-DRB1*06 and *14 gene products. This broad antigen group is produced by the major histocompatibility complex (MHC) gene complex in humans. This group is part of a larger family of genes known as the immune system genes. HLA-DR6 is an integral part of the immune response system, playing a crucial role in the regulation of immune response to pathogens.
Function[edit]
HLA-DR6, like other HLA class II molecules, is primarily responsible for presenting peptides derived from extracellular proteins to the T cells. It is expressed in antigen-presenting cells (APC), including macrophages, dendritic cells, and B cells. The interaction between HLA-DR6 and T cells is crucial for the activation of the adaptive immune response.
Association with Diseases[edit]
HLA-DR6 has been associated with several autoimmune and inflammatory diseases. These include multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. The exact mechanism of how HLA-DR6 contributes to these diseases is not fully understood, but it is believed to involve the presentation of self-peptides to T cells, leading to an autoimmune response.
Genetic Diversity[edit]
The HLA-DR6 gene exhibits a high degree of polymorphism, meaning that there are many different versions of the gene in the human population. This genetic diversity is believed to be a result of evolutionary pressure from various pathogens, as different HLA-DR6 variants can present different sets of peptides to T cells.
See Also[edit]
-
DR Illustration
